Athira Pharma completes patient dosing in Phase 2/3 trial of fosgonimeton in AD
Athira Pharma, Inc. (NASDAQ: ATHA), a prominent biopharmaceutical company specializing in neurodegenerative diseases, has announced the completion of patient dosing in the Phase 2/3 LIFT-AD ... Read More
Zydus Lifesciences wraps up enrollment for Phase II ALS trial of Usnoflast
Zydus Lifesciences, a renowned global pharmaceutical company, has achieved a significant milestone by completing the enrollment for the Phase II clinical trial of its novel ... Read More